Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 3Neoplasms 2Thoracic Neoplasms 1Squamous Non-small Cell Lung Cancer 1Squamous Non Small Cell Lung Cancer 1Solid Tumors 1Solid Tumor, Adult 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Non-small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Irinotecan 7Bevacizumab 7Injections 6Cetuximab 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5Capecitabine 5tocilizumab 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3pazopanib 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Tumors × necitumumab × Clear all
NCT01624467 2016-07-25

A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors

Eli Lilly and Company

Phase 2 Completed
75 enrolled 12 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡